Summit Therapeutics Inc (NASDAQ: SMMT) on Tuesday, soared 16.13% from the previous trading day, before settling in for the closing price of $19.03. Within the past 52 weeks, SMMT’s price has moved between $2.10 and $33.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -28.65% over the past five years. The company achieved an average annual earnings per share of 70.17%. With a float of $114.59 million, this company’s outstanding shares have now reached $737.09 million.
Let’s look at the performance matrix of the company that is accounted for 105 employees. In terms of profitability, gross margin is 385.96%, operating margin of 77226.38%, and the pretax margin is 83760.85%.
Summit Therapeutics Inc (SMMT) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Summit Therapeutics Inc is 84.45%, while institutional ownership is 11.50%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 70.17% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Summit Therapeutics Inc (SMMT) is currently performing well based on its current performance indicators. A quick ratio of 8.31 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Summit Therapeutics Inc (NASDAQ: SMMT) saw its 5-day average volume 2.99 million, a positive change from its year-to-date volume of 2.59 million. As of the previous 9 days, the stock’s Stochastic %D was 91.75%. Additionally, its Average True Range was 1.38.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 46.72%, which indicates a significant decrease from 99.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.80% in the past 14 days, which was lower than the 116.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.75, while its 200-day Moving Average is $13.43. Nevertheless, the first resistance level for the watch stands at $23.06 in the near term. At $24.01, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.92. If the price goes on to break the first support level at $20.20, it is likely to go to the next support level at $18.29. The third support level lies at $17.34 if the price breaches the second support level.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
Market capitalization of the company is 16.29 billion based on 737,448K outstanding shares. Right now, sales total 0 K and income totals -614,930 K. The company made 0 K in profit during its latest quarter, and -56,250 K in sales during its previous quarter.
